TNF Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: QCLS · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $2, $600,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-update
TL;DR
TNF Pharma inked a deal & sold some stock, filing shows.
AI Summary
On October 1, 2024, TNF Pharmaceuticals, Inc. (formerly MyMD Pharmaceuticals, Inc.) entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- October 1, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by TNF Pharmaceuticals, Inc. on October 1, 2024?
The filing does not specify the details of the material definitive agreement, only that one was entered into on October 1, 2024.
What were the details of the unregistered sales of equity securities reported in this 8-K?
The filing mentions unregistered sales of equity securities but does not provide specific details regarding the number of shares, price, or purchasers.
What other events are reported in this 8-K filing?
Besides the material definitive agreement and unregistered equity sales, the filing also indicates 'Other Events' and the inclusion of 'Financial Statements and Exhibits'.
When did TNF Pharmaceuticals, Inc. change its name from MyMD Pharmaceuticals, Inc.?
TNF Pharmaceuticals, Inc. changed its name from MyMD Pharmaceuticals, Inc. on April 20, 2021.
What is the primary business of TNF Pharmaceuticals, Inc. according to its SIC code?
TNF Pharmaceuticals, Inc. is classified under SIC code 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 962 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-10-07 16:05:30
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
- $2 — Stock"), at a price per share equal to $2.12, which was 120.0% of the dollar volu
- $600,000 — Company from the Private Placement were $600,000 (the "Purchase Price"). The Company int
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 43KB
- ex99-1.htm (EX-99.1) — 21KB
- 0001493152-24-040276.txt ( ) — 295KB
- tnfa-20241001.xsd (EX-101.SCH) — 3KB
- tnfa-20241001_lab.xml (EX-101.LAB) — 33KB
- tnfa-20241001_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: October 7, 2024 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Director